Dana-Farber experts recommend actionable steps to enhance the rigor and transparency of FDA validation standards for radiology AI software.
Key Details
- 1The current FDA regulatory framework for SaMD validation is flexible but lacks explicit, consistent standards for radiology AI.
- 2Common radiology SaMD types include CADq, CADt, CADe, CADx, CADe/x, and CADa/o.
- 3Retrospective validation is typical for assistive radiology AI; prospective studies are standard for autonomous devices.
- 4Concerns exist over inadequate evaluation metrics for generative models and the use of synthetic data for some devices.
- 5Recommendations include removing nonclinical validation for certain devices, requiring more reader and prospective studies, adopting mandatory reporting checklists, and creating a public validation database.
Why It Matters
Clear and consistent FDA standards are crucial for ensuring the clinical reliability, performance, and reporting transparency of AI tools used in radiology, directly impacting adoption and trust among professionals and patients.
Source
AuntMinnie
Related News
•Radiology Business
Radiology AI Devices at Elevated Risk for FDA Recalls, Study Finds
Radiology AI devices are more likely to face FDA recalls, largely due to deviations from intended use and incomplete clinical data.
•AuntMinnie
ONC Official at SIIM Calls for Smarter AI and Better Image Sharing
ONC's Dr. Jason Funderburk urges improvements in medical image sharing and AI readiness at SIIM 2024.
•HealthExec
House Moves to Block AI-Driven Medicare Prior Authorization Pilot
A U.S. House committee voted to block the expansion of an AI-driven Medicare prior authorization pilot active in six states.